Aethlon Medical(AEMD) - 2026 Q3 - Quarterly Results

Financial Performance - Aethlon Medical reported a cash balance of approximately $7.0 million as of December 31, 2025[9]. - Consolidated operating expenses for the three months ended December 31, 2025, were approximately $2.06 million, an increase of $250,000 or 13.6% from $1.81 million in the same period in 2024[10]. - Operating expenses for the nine months ended December 31, 2025, decreased by approximately $1.98 million or 26.9%, totaling approximately $5.36 million compared to $7.34 million for the same period in 2024[12]. - Other income, primarily interest income, totaled $44,000 for the three months ended December 31, 2025, compared to $60,000 in the prior-year period[11]. - Net loss for the three months ended 12/31/25 was $2,018,245, compared to a net loss of $1,754,783 for the same period in 2024, indicating an increase of 15.1%[26]. - Net loss for the nine months ended 12/31/25 was $5,267,203, a decrease of 26.1% compared to $7,133,196 for the same period in 2024[26]. - Comprehensive loss for the three months ended 12/31/25 was $2,021,705, compared to $1,767,840 for the same period in 2024, representing a 14.4% increase[26]. Cost Management - The company maintained disciplined cost controls, resulting in lower year-to-date operating expenses compared to the prior year[5]. - Total operating expenses for the three months ended 12/31/25 were $2,062,116, an increase from $1,814,747 for the same period in 2024, representing a 13.6% rise[26]. - Total operating expenses for the nine months ended 12/31/25 were $5,364,335, down 26.9% from $7,337,402 for the same period in 2024[26]. - Payroll and related expenses for the three months ended 12/31/25 were $987,424, an increase of 59.1% from $620,487 in the same period last year[26]. - General and administrative expenses for the three months ended 12/31/25 were $741,650, a decrease of 9.2% from $816,383 for the same period in 2024[26]. Clinical Development - Enrollment and treatment of participants in Cohort 2 of the Australian oncology trial is actively underway, building on favorable results from Cohort 1[4]. - The Hemopurifier is being evaluated for compatibility with a simplified blood treatment system, potentially broadening its clinical application[5]. - Aethlon's preclinical Long COVID research demonstrated that the GNA affinity resin binds EVs from patient samples, supporting the Hemopurifier's potential as a multi-indication therapeutic approach[6]. - The company continues to advance its clinical programs and research initiatives with operational discipline, aiming to deliver therapeutic solutions for cancer and life-threatening infectious diseases[9]. Shareholder Information - Basic and diluted loss per share attributable to common stockholders for the three months ended 12/31/25 was $2.45, a significant improvement from $10.05 in the same period last year[26]. - Weighted average number of common shares outstanding for the three months ended 12/31/25 was 823,126, significantly higher than 174,529 for the same period in 2024[26]. Asset Management - The total assets of Aethlon Medical as of December 31, 2025, were approximately $8.06 million, an increase from $7.36 million as of March 31, 2025[24].